Defining a new testosterone threshold for medical castration: Results from a prospective cohort series

Journal of the Canadian Urological Association

Volumn 7, Issue 5-6, 2013, Pages

  Dason, Shawn ^a   Allard, Christopher B ^a   Tong, Justin ^a   Shayegan, Bobby ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84877836512     PISSN: 19116470     EISSN: None     Source Type: Journal    
DOI: 10.5489/cuaj.471     Document Type: Article

References (28)

1. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002;167(2 Pt 2):948-951; discussion 952. http://dx.doi.org/10.1016/S0022-5347(02)80307-X
2. Murphy WM, Soloway MS, Barrows GH. Pathologic changes associated with androgen deprivation therapy for prostate cancer. Cancer 1991;68:821-828. http://dx.doi.org/10.1002/1097-0142(19910815)68:4821::AID-CNCR28206804263.0.CO;2-S
3. Civantos F, Marcial MA, Banks ER, et al. Pathology of androgen deprivation therapy in prostate carcinoma. A comparative study of 173 patients. Cancer 1995;75:1634-1641. http://dx.doi.org/10.1002/1097-0142(19950401)75:71634::AID-CNCR28207507133.0.CO;2-#
4. Djavan B, Eastham J, Gomella L, et al. Testosterone in prostate cancer: the Bethesda consensus. BJU Int 2012;110:344-352. http://dx.doi.org/10.1111/j.1464-410X.2011.10719.x. Epub 2011 Nov 30.
5. Tombal B. Appropriate Castration with Luteinising Hormone Releasing Hormone (LHRH) Agonists: What is the Optimal Level of Testosterone? European Urology Supplements 2005;4:14-19. http://dx.doi.org/10.1016/j.eursup.2005.04.004
6. Oefelein MG, Feng A, Scolieri MJ, et al. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology 2000;56:1021-1024. http://dx.doi.org/10.1016/S0090-4295(00)00793-7
7. Schally AV, Arimura A, Baba Y, et al. Isolation and properties of the FSH and LH-releasing hormone. Biochem Biophys Res Commun 1971;43:393-399. http://dx.doi.org/10.1016/0006-291X(71)90766-2
8. Wilke TJ, Utley DJ. Total testosterone, free-androgen index, calculated free testosterone, and free testosterone by analog RIA compared in hirsute women and in otherwise-normal women with altered binding of sex-hormone-binding globulin. Clin Chem 1987;33:1372-1375.
9. Schulman CC, Irani J, Morote J, et al. Testosterone measurement in patients with prostate cancer. Eur Urol 2010;58:65-74. http://dx.doi.org/10.1016/j.eururo.2010.04.001
10. Wheeler MJ, D'Souza A, Matadeen J, et al. Ciba Corning ACS:180 testosterone assay evaluated. Clin Chem 1996;42:1445-1449.
11. Perachino M, Cavalli V, Bravi F. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance? BJU Int 2010;105:648-651. http://dx.doi.org/10.1111/j.1464-410X.2009.08814.x
12. Morote J, Orsola A, Planas J, et al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol 2007;178(4 Pt 1):1290-1295. http://dx.doi.org/10.1016/j.juro.2007.05.129
13. Tombal B, Berges R. Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen-Deprivation Therapy. European Urology Supplements 2008;7:15-21. http://dx.doi.org/10.1016/j.eursup.2007.11.001
14. National Comprehensive Cancer Network (U.S.). The complete library of NCCN clinical practice guidelines in oncology. National Comprehensive Cancer Network: Rockledge, PA, 2003.
15. Mottet N, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011;59:572-583. http://dx.doi.org/10.1016/j.eururo.2011.01.025
16. Taieb J, Mathian B, Millot F, et al. Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women, and children. Clin Chem 2003;49:1381-1395. http://dx.doi.org/10.1373/49.8.1381
17. van der Sluis TM, Vis AN, van Moorselaar RJ, et al. Intraprostatic testosterone and dihydrotestosterone. Part I: concentrations and methods of determination in men with benign prostatic hyperplasia and prostate cancer. BJU Int 2012;109:176-182. http://dx.doi.org/10.1111/j.1464-410X.2011.10651.x
18. Morote J, Planas J, Salvador C, et al. Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy. BJU Int 2009;103:332-335; discussion 335. http://dx.doi.org/10.1111/j.1464-410X.2008.08062.x
19. van der Sluis TM, Bui HN, Meuleman EJ, et al. Lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry. J Urol 2012;187:1601-1606. http://dx.doi.org/10.1016/j.juro.2011.12.063
20. Zlotta A, Debruyne FMJ. Expert Opinion on Optimal Testosterone Control in Prostate Cancer. European Urology Supplements 2005;4:37-41. http://dx.doi.org/10.1016/j.eursup.2005.08.005
21. Nora SD, Shayegan B. Inconsistent Testosterone Monitoring and Antiandrogen Use in Prostate Cancer Patients Receiving Androgen Deprivation Therapy [abstr UP-050]. Can Urol Assoc J 2012;6:S83.
22. Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010;362:1192-1202. http://dx.doi.org/10.1056/NEJMoa0908127
23. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-224. http://dx.doi.org/10.1056/NEJMoa030660
24. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005. http://dx.doi.org/10.1056/NEJMoa1014618
25. Ryan CJ, Smith MR, De Bono JS, et al. Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 30, 2012. [suppl; abstr LBA4518].
26. Taplin M-E, Montgomery RB, Logothetis C, et al. Effect of neoadjuvant abiraterone acetate (AA) plus leuprolide acetate (LHRHa) on PSA, pathological complete response (pCR), and near pCR in localized high-risk prostate cancer (LHRPC): Results of a randomized phase II study. J Clin Oncol 30, 2012 [suppl; abstr 4521].
27. Ryan CJ, Tindall DJ. Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J Clin Oncol 2011;29:3651-3658. http://dx.doi.org/10.1200/JCO.2011.35.2005
28. Scher HI, Fizazi K, Saad F, et al. Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study. J Clin Oncol 30, 2012 [suppl 5; abstr LBA1].